Synergistic Effects of Erlotinib and Everolimus on Bronchial Carcinoids and Large-Cell Neuroendocrine Carcinomas with Activated EGFR/AKT/mTOR Pathway

Publisher： Karger

E-ISSN： 1423-0194|96|3|228-237

ISSN： 0028-3835

Source： Neuroendocrinology, Vol.96, Iss.3, 2012-02, pp. : 228-237

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Octreotide and the mTOR Inhibitor RAD001 (Everolimus) Block Proliferation and Interact with the Akt-mTOR-p70S6K Pathway in a Neuro-Endocrine Tumour Cell Line

By  

Neuroendocrinology, Vol. 87, Iss. 3, 2007-11 ,pp. : 168-181

Karger

Access to resources Recommend Favorite

The Novel mTOR Inhibitor RAD001 (Everolimus) Induces Antiproliferative Effects in Human Pancreatic Neuroendocrine Tumor Cells

By  

Neuroendocrinology, Vol. 85, Iss. 1, 2007-02 ,pp. : 54-60

Karger

Access to resources Recommend Favorite

VEGF Secretion by Neuroendocrine Tumor Cells Is Inhibited by Octreotide and by Inhibitors of the PI3K/AKT/mTOR Pathway

By  

Neuroendocrinology, Vol. 91, Iss. 3, 2010-04 ,pp. : 268-278

Karger

Access to resources Recommend Favorite

Antitumor Effect of Everolimus in Preclinical Models of High-Grade Gastroenteropancreatic Neuroendocrine Carcinomas

By  

Neuroendocrinology, Vol. 97, Iss. 4, 2013-01 ,pp. : 331-340

Karger

Access to resources Recommend Favorite

Interleukin-1β Plays a Pivotal Role via the PI3K/Akt/mTOR Signaling Pathway in the Chronicity of Mesial Temporal Lobe Epilepsy

By  

Neuroimmunomodulation, Vol. 23, Iss. 5-6, 2017-04 ,pp. : 332-344

Karger

Access to resources Recommend Favorite